← Oncology Approval Tracker

FDA DECISION ·

Zynlonta

loncastuximab tesirine-lpyl · ADC Therapeutics

Accelerated approvalNew therapyLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory large B-cell lymphoma after two or more systemic treatment lines, including DLBCL, DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma.

LAMPGEN ANALYSIS

Why it matters

The CD19-directed antibody-drug conjugate adds a later-line approach for specified aggressive lymphomas.

What research teams should watch

Record the exact lymphoma subtype and prior line count and follow cytopenias and treatment interruptions.

PRIMARY RECORDS

Sources